GALACTIC-HF Subgroup Analysis: Omecamtiv Mecarbil Effective Across Ethnic Groups | Dr David Lanfear

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this video, Professor David Lanfear (Henry Ford Hospital, Detroit, MI, US) discusses a subgroup analysis of GALACTIC-HF which aimed to evaluate the effect of omecamtiv mecarbil in black patients with heart failure (HF) with reduced ejection fraction (HFrEF). Originally presented at HFSA 2021, the additional results suggest that the outcomes in black patients treated with this drug are similar to those in the overall population of the trial and white patients, showing the drug is effective and safe to use across ethnic groups.

Discussion Points:
-Importance of this subgroup analysis
-Study design and patient population
-Key findings
-Impact on practice and further research
-Take-home messages

Recorded Remotely from Detroit, 2021.
Interviewer: Jordan Rance

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.